Otsuka Holdings Co Ltd
TSE:4578

Watchlist Manager
Otsuka Holdings Co Ltd Logo
Otsuka Holdings Co Ltd
TSE:4578
Watchlist
Price: 9 315 JPY 1.03% Market Closed
Market Cap: 5.1T JPY

Otsuka Holdings Co Ltd
Tax Provision

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Otsuka Holdings Co Ltd
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
Otsuka Holdings Co Ltd
TSE:4578
Tax Provision
-ÂĄ18.9B
CAGR 3-Years
14%
CAGR 5-Years
14%
CAGR 10-Years
12%
Takeda Pharmaceutical Co Ltd
TSE:4502
Tax Provision
-ÂĄ64.6B
CAGR 3-Years
-37%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Daiichi Sankyo Co Ltd
TSE:4568
Tax Provision
-ÂĄ46.4B
CAGR 3-Years
-43%
CAGR 5-Years
-57%
CAGR 10-Years
3%
S
Shionogi & Co Ltd
TSE:4507
Tax Provision
-ÂĄ35.1B
CAGR 3-Years
-11%
CAGR 5-Years
2%
CAGR 10-Years
-2%
Chugai Pharmaceutical Co Ltd
TSE:4519
Tax Provision
-ÂĄ156.2B
CAGR 3-Years
12%
CAGR 5-Years
-17%
CAGR 10-Years
-21%
Astellas Pharma Inc
TSE:4503
Tax Provision
-ÂĄ11.9B
CAGR 3-Years
33%
CAGR 5-Years
18%
CAGR 10-Years
15%
No Stocks Found

Otsuka Holdings Co Ltd
Glance View

Otsuka Holdings Co. Ltd. began its journey in 1921 as a small chemicals company in Naruto, Japan. Its evolution from those humble beginnings to a global pharmaceutical giant is marked by its relentless commitment to innovation and expansion. Today, Otsuka operates as a holding company, orchestrating a diversified portfolio across pharmaceuticals, nutraceuticals, consumer products, and medical devices. It has cultivated a unique philosophy: a balance between large-scale operations and niche markets. The company’s pharmaceutical sector, its most significant revenue contributor, is driven largely by advancements in CNS (central nervous system) treatments and nephrology. The success of its flagship product, Abilify, a leading antipsychotic, underscores Otsuka’s ability to combine market demands with cutting-edge research to sustain growth and profitability. In parallel, Otsuka nurtures its nutraceuticals wing, embodied by its signature Pocari Sweat and SoyJoy brands. These products epitomize the company’s strategy of creating and expanding niche markets, offering health-oriented products that resonate with evolving consumer health trends. This diversification into consumer products and nutraceuticals not only complements its pharmaceutical endeavors but also mitigates risks by tapping into varied revenue streams. By focusing on health and wellness broadly, Otsuka Holdings strategically positions itself to navigate the complexities of the global healthcare market, ensuring a resilient business model. Through this multifaceted approach, Otsuka sustains its growth, reaffirming its legacy as a dynamic and globally influential company.

Intrinsic Value
9 401.16 JPY
Undervaluation 1%
Intrinsic Value
Price

See Also

What is Otsuka Holdings Co Ltd's Tax Provision?
Tax Provision
-18.9B JPY

Based on the financial report for Sep 30, 2025, Otsuka Holdings Co Ltd's Tax Provision amounts to -18.9B JPY.

What is Otsuka Holdings Co Ltd's Tax Provision growth rate?
Tax Provision CAGR 10Y
12%

Over the last year, the Tax Provision growth was 38%. The average annual Tax Provision growth rates for Otsuka Holdings Co Ltd have been 14% over the past three years , 14% over the past five years , and 12% over the past ten years .

Back to Top